Clinical Trials
18 trialsNCT05099848 2026-05-22
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Completed
NCT07314372 2026-01-20
FAD-HCC-001
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT07324473 2026-01-07
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
First Affiliated Hospital of Chongqing Medical University
Phase 2 Not yet recruiting
NCT07157969 2025-12-01
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT07100392 2025-08-17
LEAF-02
Fudan University
Phase 2 Recruiting
NCT05003700 2024-11-05
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Completed
NCT06546280 2024-08-09
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
Zhujiang Hospital
Phase 2 Not yet recruiting
NCT04483284 2024-08-01
Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
Shanghai Zhongshan Hospital
Phase 2 Active not recruiting
NCT06363825 2024-04-17
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Fujian Medical University
Phase 2 Recruiting
NCT04930315 2023-06-13
CAPT
Zhejiang University
Phase 2 Unknown
NCT05048017 2023-03-29
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05171309 2021-12-28
Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT05135364 2021-11-26
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT04724226 2021-09-05
C-couple
Sun Yat-sen University
Phase 2 Unknown
NCT04479527 2021-01-14
Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04297202 2020-08-07
HCC-009
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04014101 2019-07-11
SHR-1210
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT03793725 2019-01-04
HZ-T-PD1-APA
Harbin Medical University
Phase 2 Unknown